Infant Bacterial Therapeutics Management
Management criteria checks 3/4
Infant Bacterial Therapeutics' CEO is Staffan Stromberg, appointed in Jan 2013, has a tenure of 11.25 years. total yearly compensation is SEK5.33M, comprised of 57.9% salary and 42.1% bonuses, including company stock and options. directly owns 0.79% of the company’s shares, worth €803.01K. The average tenure of the management team and the board of directors is 0.9 years and 6.9 years respectively.
Key information
Staffan Stromberg
Chief executive officer
kr5.3m
Total compensation
CEO salary percentage | 57.9% |
CEO tenure | 11.3yrs |
CEO ownership | 0.8% |
Management average tenure | less than a year |
Board average tenure | 6.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | kr5m | kr3m | -kr123m |
Sep 30 2023 | n/a | n/a | -kr122m |
Jun 30 2023 | n/a | n/a | -kr99m |
Mar 31 2023 | n/a | n/a | -kr69m |
Dec 31 2022 | kr6m | kr3m | -kr65m |
Sep 30 2022 | n/a | n/a | -kr42m |
Jun 30 2022 | n/a | n/a | -kr34m |
Mar 31 2022 | n/a | n/a | -kr65m |
Dec 31 2021 | kr5m | kr3m | -kr45m |
Sep 30 2021 | n/a | n/a | -kr55m |
Jun 30 2021 | n/a | n/a | -kr74m |
Mar 31 2021 | n/a | n/a | -kr73m |
Dec 31 2020 | kr4m | kr2m | -kr72m |
Sep 30 2020 | n/a | n/a | -kr73m |
Jun 30 2020 | n/a | n/a | -kr65m |
Mar 31 2020 | n/a | n/a | -kr44m |
Dec 31 2019 | kr3m | kr2m | -kr46m |
Sep 30 2019 | n/a | n/a | -kr43m |
Jun 30 2019 | n/a | n/a | -kr40m |
Mar 31 2019 | n/a | n/a | -kr32m |
Dec 31 2018 | kr3m | kr2m | -kr41m |
Sep 30 2018 | n/a | n/a | -kr26m |
Jun 30 2018 | n/a | n/a | -kr22m |
Mar 31 2018 | n/a | n/a | -kr37m |
Dec 31 2017 | kr3m | kr1m | -kr36m |
Compensation vs Market: Staffan's total compensation ($USD489.06K) is about average for companies of similar size in the German market ($USD401.52K).
Compensation vs Earnings: Staffan's compensation has been consistent with company performance over the past year.
CEO
Staffan Stromberg (56 yo)
11.3yrs
Tenure
kr5,327,000
Compensation
Mr. Staffan Stromberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Stromberg served as Director at Genetic Analysis AS since October 28, 2020 u...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 11.3yrs | kr5.33m | 0.79% SEK 803.0k | |
Chief Financial Officer | 1.6yrs | no data | 0.023% SEK 22.9k | |
Chief Operating Officer | 6.3yrs | kr500.00k | 0.083% SEK 84.1k | |
Chief Scientific Officer | less than a year | no data | no data | |
Head of Medical Affairs | less than a year | no data | no data | |
Chief Medical Officer | less than a year | no data | no data |
0.9yrs
Average Tenure
56yo
Average Age
Experienced Management: 9IB's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman | 13.3yrs | kr727.00k | no data | |
Independent Director | 8.6yrs | kr153.00k | 0.032% SEK 32.2k | |
Independent Director | 6.9yrs | kr153.00k | 0.0027% SEK 2.7k | |
Independent Director | 5.9yrs | kr153.00k | 0.00074% SEK 748.8 | |
Independent Director | 6.9yrs | kr193.00k | 0.056% SEK 56.7k |
6.9yrs
Average Tenure
57yo
Average Age
Experienced Board: 9IB's board of directors are considered experienced (6.9 years average tenure).